The CAI, NIH & NCI Partnership: The NCI Invention Portfolio for High Commercial Potential Based on CAI’s Proprietary and Rigorous Business Market and Scientific Criteria
Bethesda, Maryland (PRWEB) August 01, 2013 -- The Center for Advancing Innovation, INC (CAI), a globally focused private-public partnership with an over-arching mission to drive successful innovation entered into a Partnership Intermediary Agreement (PIA) with the National Institutes of Health’s (NIH) Office of Technology Transfer (OTT) and the National Cancer Institute (NCI) Technology Transfer Center (TTC).
As a partnership intermediary for NIH OTT and the NCI, the team from CAI, which includes over 20 Ph.D.s, MBAs and other analysts, is assisting the NCI and NIH to accelerate the commercialization of NCI technologies. Using CAI’s robust and unique portfolio assessment model, the partners are working together to evaluate the NCI patent portfolio consisting of thousands of NCI intramural technologies in the areas of drugs, vaccines, therapeutics, diagnostics and medical devices. Through this assessment model, CAI, NCI and NIH have worked together to identify those inventions anticipated to have significant impact on the public health. Recently we reached a significant milestone, as we have identified the top 50 near-term, commercially viable inventions. CAI will also coordinate interest with small businesses, the biopharmaceutical industry and educational institutions to match NCI technologies for possible collaboration and transfer for commercialization.
According to Tom Stackhouse, Associate Director of the Technology Transfer Center at NCI, the NCI TTC and NIH OTT will be working with CAI to accelerate and increase the volume of commercial development and licensing of innovative technologies coming from the NCI and NIH intramural research programs. He also noted that NCI is already seeing the benefit from this partnership via several new opportunities between potential licensees, collaboration partners and NIH inventors.
“CAI’s partnership with the NIH and NCI is an ideal foundation to commercialize intramural inventions and make a sustainable impact on world health and the nation’s economy,” said Rosemarie Truman, CAI Founder and CEO. “We’re strongly encouraged about our collective team’s progress and we are in the process of engaging economic development organizations, entrepreneurs, foundations, large pharmas and other organizations as potential partners to perform additional R&D with the NCI labs.”
The most exciting phase of this new partnership is developing new models for moving technology from the NCI labs to the commercial sector. Stay tuned for upcoming news about this partnership’s plans to launch a new and exciting commercialization event.
About The Center for Advancing Innovation (CAI)
The Center for Advancing Innovation is global innovation intermediary focused on commercializing market viable innovations, increasing the success of startups and entrepreneurship and making an economic impact with these efforts. CAI focuses on all industries; at present, the focus is biotechnology, biopharma, medical devices, healthcare services, Health IT, e-health, mobile health, electronic medical records, health informatics, biohealth cyber security, high tech as well as internet/social media type inventions. For more information, please visit http://www.thecenterforadvancinginnovation.org.
About the NIH Office of Technology Transfer (NIH OTT)
OTT manages the patenting and licensing of a wide range of inventions made by scientists working for the NIH and FDA intramural research programs as mandated by the Federal Technology Transfer Act and related legislation. OTT also facilitates access to NIH and FDA inventions by developing research relationships between NIH and FDA intramural scientists with researchers in businesses and higher educational institutions. More information can be found at http://www.ott.nih.gov.
About the NCI Technology Transfer Center (NCI TTC)
NCI TTC serves as the Institute’s focal point for implementation of the Federal Technology Transfer Act by working closely with NCI investigators and outside parties to facilitate commercialization efforts to benefit public health. In this role it manages the NCI patent portfolio and utilizes these patents as incentive for commercial development of technologies, and establishes formal collaborative R&D partnerships among academia, federal laboratories, and industry.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
Rosemarie Truman, The Center for Advancing Innocation, (202) 438-2208, [email protected]
Share this article